TEMPEST THERAPEUTICS INC. - COMMON STOCK

Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights

13 май 2022 08:00:00 Источник Nasdaq GlobeNewswire

Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting

27 апр 2022 10:01:00 Источник Nasdaq GlobeNewswire

Tempest Announces Private Placement Financing of $15 Million

27 апр 2022 08:00:02 Источник Nasdaq GlobeNewswire

Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting

08 апр 2022 13:00:00 Источник Nasdaq GlobeNewswire

Tempest Reports Year End 2021 Financial Results and Provides Business Update

29 мар 2022 16:00:00 Источник Nasdaq GlobeNewswire

Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference

10 мар 2022 08:00:01 Источник Nasdaq GlobeNewswire

Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

08 мар 2022 16:30:00 Источник Nasdaq GlobeNewswire

Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference

09 фев 2022 08:00:03 Источник Nasdaq GlobeNewswire

Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab

18 ноя 2021 08:00:02 Источник Nasdaq GlobeNewswire

Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer

12 ноя 2021 07:00:02 Источник Nasdaq GlobeNewswire

Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights

10 ноя 2021 16:05:01 Источник Nasdaq GlobeNewswire

Tempest to Present at Two Upcoming Investor Conferences in November

09 ноя 2021 08:00:02 Источник Nasdaq GlobeNewswire

Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495

08 ноя 2021 08:00:01 Источник Nasdaq GlobeNewswire

Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

01 окт 2021 08:00:01 Источник Nasdaq GlobeNewswire

Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche

20 сен 2021 08:00:02 Источник Nasdaq GlobeNewswire

Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target

13 сен 2021 08:00:01 Источник Nasdaq GlobeNewswire

Tempest to Present at Upcoming Investor Conferences

09 сен 2021 16:01:00 Источник Nasdaq GlobeNewswire